The drug has promising data in hand in diffuse large B cell lymphoma (DLBCL), a form of non ... two well-established genes linked to cancer – MYC and MCL1 – which have traditionally been ...

Wojciech Jurczak, MD, PhD, discusses advancements in B-cell lymphoma therapy, focusing on immunotherapy, molecular-targeted agents, and more.

Wojciech Jurczak, MD, PhD, ​​discusses the future of B-cell lymphoma therapy, with a focus on Bruton's tyrosine kinase ...

A rare case has been reported of diffuse large B-cell lymphoma (DLBCL) presenting initially as cold agglutinin disease (CAD). The report, published in the Kaohsiung Journal of Medical Sciences, ...

B-cell lymphoma is a type of blood cancer that affects the B lymphocytes of the immune system. They usually arise in the lymph nodes or in other lymphoid tissue, such as the spleen, bone marrow ...

• In advanced-stage HL, reduction of chemotherapy or radiotherapy after a negative interim PET scan is probably beneficial for overall survival. • Treatment escalation with rituximab after a positive ...

This is the first report on the long-term durability of response among complete responders to mitomycin C chemoablation of low-grade upper tract urothelial carcinoma.

Exelixis, Inc announced that the U.S. Food and Drug Administration (FDA) has approved CABOMETYX® (cabozantinib) for the treatment of 1) adult and pediatric patients 12 years of age and older with ...

Feb. 11, 2025 — Researchers have discovered a new mechanism that is used by a male sex hormone essential for muscle and bone function. The findings could lead to the development of new drugs ...

Skin (cutaneous) lymphomas often manifest as a skin rash. Although usually identified early, skin lymphomas can be mistaken for other skin conditions, delaying diagnosis. Non-Hodgkin's lymphoma (NHL) ...